Just on the heels of two approvals last week, the FDA today approved a third therapy to treat patients with multiple myeloma. Elotuzumab (Emplicity ™) is approved for use in combination with another drug, lenalidomide (Revlimid ®) for patients who have failed previous therapies.
The dizzying rate at which new therapies have come online for multiple myeloma has created quite a bit of buzz, just ahead of the annual American Society of Hematology Meeting kicking off in Orlando this weekend. We anticipate that we will be hearing a lot more about these new therapies for myeloma, as well as many emerging therapies for other forms of blood cancer during the conference.
LLS applauded last week’s approval of daratumumab and ixazomib, (click here), and we are pleased to see yet another new option for patients for this largely incurable disease.